Tools for Anti-Inflammatory Drug Design: In Vitro Models of Leukocyte Migration

Medicinal Research Reviews

Volumn 24, Issue 3, 2004, Pages 267-298

  Frow, Emma K ^a   Reckless, Jill ^a   Grainger, David J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Chemotaxis; Filter migration assay; Inflammation; Inhibitor; Leukocyte

Indexed keywords

AGAROSE; ANTIINFLAMMATORY AGENT; BUFFER; CALCIUM; CHEMOATTRACTANT; COMPLEMENT COMPONENT C5A; FORMYLMETHIONYLLEUCYLPHENYLALANINE; G PROTEIN COUPLED RECEPTOR; HYDROXYICOSATETRAENOIC ACID; INTERLEUKIN 8; LEUKOTRIENE B4; LYSOPHOSPHOLIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E2; RANTES; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CHEMOTACTIC FACTOR;

ANTIINFLAMMATORY ACTIVITY; CALCIUM TRANSPORT; CELL MOTION; CELL SIZE; CELL TYPE; CELL VIABILITY; CHEMOKINESIS; DRUG DESIGN; DRUG IDENTIFICATION; DRUG SCREENING; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; LEUKOCYTE MIGRATION INHIBITION; NONHUMAN; REVIEW; SHEAR FLOW; BIOLOGICAL MODEL; CHEMISTRY; CLASSIFICATION; DRUG EFFECT; LEUKOCYTE; LEUKOCYTE MIGRATION INHIBITION TEST; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS; CELL MIGRATION INHIBITION; CHEMOTACTIC FACTORS; CHEMOTAXIS, LEUKOCYTE; DRUG DESIGN; HUMANS; LEUKOCYTES; MODELS, BIOLOGICAL;

EID: 1842852975     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10062     Document Type: Review

References (117)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
2. Rogers J, Shen Y. A perspective on inflammation in Alzheimer's disease. Ann NY Acad Sci 2000;924:132-135.
3. Sullivan GW, Sarembock IJ, Linden J. The role of inflammation in vascular diseases. J Leukoc Biol 2000;67:591-602.
4. Watanabe T, Fan J. Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis. Int J Cardiol 1998;66(Suppl 1):S45-S53; discussion S55.
5. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann NY Acad Sci 2000;908:244-254.
6. Bebo BF, Jr., Yong T, Orr EL, Linthicum DS. Hypothesis: A possible role for mast cells and their inflammatory mediators in the pathogenesis of autoimmune encephalomyelitis. J Neurosci Res 1996;45:340-348.
7. Mennicken F, Maki R, de Souza EB, Quirion R. Chemokines and chemokine receptors in the CNS: A possible role in neuroinflammation and patterning. Trends Pharmacol Sci 1999;20:73-78.
8. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-361.
9. Kunkel SL, Lukacs N, Kasama T, Strieter RM. The role of chemokines in inflammatory joint disease. J Leukoc Biol 1996;59:6-12.
10. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994;76:301-314.
11. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-568.
12. Thelen M. Dancing to the tune of chemokines. Nat Immunol 2001;2:129-134.
13. Nacy CA, Meltzer MS. T-cell-mediated activation of macrophages. Curr Opin Immunol 1991;3:330-335.
14. Citterio F. Steroid side effects and their impact on transplantation outcome. Transplantation 2001;72:S75-S80.
15. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001;2:108-115.
16. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-445.
17. Rollins BJ. Chemokines. Blood 1997;90:909-928.
18. Howard OM, Oppenheim JJ, Wang JM. Chemokines as molecular targets for therapeutic intervention. J Clin Immunol 1999;19:280-292.
19. Proudfoot AE, Power CA, Wells TN. The strategy of blocking the chemokine system to combat disease. Immunol Rev 2000;177:246-256.
20. Reckless J, Tatalick LM, Grainger DJ. The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-alpha accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo. Immunology 2001;103:244-254.
21. Onuffer JJ, Horuk R. Chemokines, chemokine receptors and small-molecule antagonists: Recent developments. Trends Pharmacol Sci 2002;23:459-467.
22. Keller HU, Wilkinson PC, Abercrombie M, Becker EL, Hirsch JG, Miller ME, Ramsey WS, Zigmond SH. A proposal for the definition of terms related to locomotion of leukocytes and other cells. J Immunol 1977;118:1912-1914.
23. Poznansky MC, Olszak IT, Foxall R, Evans RH, Luster AD, Scadden DT. Active movement of T cells away from a chemokine. Nat Med 2000;6:543-548.
24. Leber T. Uber die Entstehung der Entzundung und die Wirkung der entzundungerrengenden Schadlichkeiten. Fortschr Med 1888;4:460-464.
25. Harris H. Chemotaxis of granulocytes. J Path Bact 1953;66:135-146.
26. Harris H. Role of chemotaxis in inflammation. Physiol Rev 1954;34:529-562.
27. Bignold LP. Measurement of chemotaxis of polymorphonuclear leukocytes in vitro. The problems of the control of gradients of chemotactic factors, of the control of the cells and of the separation of chemotaxis from chemokinesis. J Immunol Methods 1988;108:1-18.
28. Valente AJ, Graves DT, Vialle-Valentin CE, Delgado R, Schwartz CJ. Purification of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. Biochemistry 1988;27:4162-4168.
29. Ming WJ, Bersani L, Mantovani A. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol 1987;138:1469-1474.
30. Monneret G, Gravel S, Diamond M, Rokach J, Powell WS. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001;98:1942-1948.
31. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA. RANTES and macrophage inflammatory protein I alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 1992;176:1489-1495.
32. Sozzani S, Luini W, Molino M, Jilek P, Bottazzi B, Cerletti C, Matsushima K, Mantovani A. The signal transduction pathway involved in the migration induced by a monocyte chemotactic cytokine. J Immunol 1991;147:2215-2221.
33. Curnock AP, Logan MK, Ward SG. Chemokine signalling: Pivoting around multiple phosphoinositide 3-kinases. Immunology 2002;105:125-136.
34. Boyden S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leukocytes. J Exp Med 1962;115:453-466.
35. Keller HU, Borel JF, Wilkinson PC, Hess MW, Cottier H. Re-assessment of Boyden's technique for measuring chemotaxis. J Immunol Methods 1972;1:165-168.
36. Zigmond SH, Hirsch JG. Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor. J Exp Med 1973;137:387-410.
37. Gee AP. Advantages and limitations of methods for measuring cellular chemotaxis and chemokinesis. Mol Cell Biochem 1984;62:5-11.
38. Falk W, Goodwin RH, Jr., Leonard EJ. A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration. J Immunol Methods 1980;33:239-247.
39. Buettner HM, Lauffenburger DA, Zigmond SH. Measurement of leukocyte motility and chemotaxis parameters with the Millipore filter assay. J Immunol Methods 1989;123:25-37.
40. Lauffenburger DA, Zigmond SH. Chemotactic factor concentration gradients in chemotaxis assay systems. J Immunol Methods 1981;40:45-60.
41. Bignold LP. A novel polycarbonate (nuclepore) membrane demonstrates chemotaxis, unaffected by chemokinesis, of polymorphonuclear leukocytes in the Boyden chamber. J Immunol Methods 1987; 105:275-280.
42. Islam LN, McKay IC, Wilkinson PC. The use of collagen or fibrin gels for the assay of human neutrophil chemotaxis. J Immunol Methods 1985;85:137-151.
43. Moghe PV, Nelson RD, Tranquillo RT. Cytokine-stimulated chemotaxis of human neutrophils in a 3-D conjoined fibrin gel assay. J Immunol Methods 1995;180:193-211.
44. Franitza S, Alon R, Lider O. Real-time analysis of integrin-mediated chemotactic migration of T lymphocytes within 3-D extracellular matrix-like gels. J Immunol Methods 1999;225:9-25.
45. Haston WS, Shields JM, Wilkinson PC. Lymphocyte locomotion and attachment on two-dimensional surfaces and in three-dimensional matrices. J Cell Biol 1982;92:747-752.
46. Brown AF. Neutrophil and monocyte behavior in three-dimensional collagen matrices. Scan Electron Microsc. 1984;Part 2:747-754.
47. Wilkinson PC. Cell locomotion and chemotaxis: Basic concepts and methodological approaches. Methods 1996;10:74-81.
48. Haddox JL, Pfister RR, Sommers CI. A visual assay for quantitating neutrophil chemotaxis in a collagen gel matrix. A novel chemotactic chamber. J Immunol Methods 1991;141:41-52.
49. Johnston B, Butcher EC. Chemokines in rapid leukocyte adhesion triggering and migration. Semin Immunol 2002;14:83-92.
50. Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 1998;279:381-384.
51. Roth SJ, Carr MW, Rose SS, Springer TA. Characterization of transendothelial chemotaxis of T lymphocytes. J Immunol Methods 1995;188:97-116.
52. Casale TB, Abbas MK. Comparison of leukotriene B4-induced neutrophil migration through different cellular barriers. Am J Physiol 1990;258:C639-C647.
53. Erger RA, Casale TB. Interleukin-8 is a potent mediator of eosinophil chemotaxis through endothelium and epithelium. Am J Physiol 1995;268:L117-L122.
54. Mohan K, Ding Z, Hanly J, Issekutz TB. IFN-gamma-inducible T cell alpha chemoattractant is a potent stimulator of normal human blood T lymphocyte transendothelial migration: Differential regulation by IFN-gamma and TNF-alpha. J Immunol 2002;168:6420-6428.
55. Muller WA, Weigl SA. Monocyte-selective transendothelial migration: Dissection of the binding and transmigration phases by an in vitro assay. J Exp Med 1992;176:819-828.
56. Andjelkovic AV, Zochowski MR, Morgan F, Pachter JS. Qualitative and quantitative analysis of monocyte transendothelial migration by confocal microscopy and three-dimensional image reconstruction. In Vitro Cell Dev Biol Anim 2001;37:111-120.
57. Pietschmann P, Cush JJ, Lipsky PE, Oppenheimer-Marks N. Identification of subsets of human T cells capable of enhanced transendothelial migration. J Immunol 1992;149:1170-1178.
58. Cinamon G, Shinder V, Alon R. Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat Immunol 2001;2:515-522.
59. Weber KS, von Hundelshausen P, Clark-Lewis I, Weber PC, Weber C. Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow. Eur J Immunol 1999;29:700-712.
60. Kitayama J, Hidemura A, Saito H, Nagawa H. Shear stress affects migration behavior of polymorphonuclear cells arrested on endothelium. Cell Immunol 2000;203:39-46.
61. Cinamon G, Alon R. A real time in vitro assay for studying leukocyte transendothelial migration under physiological flow conditions. J Immunol Methods 2003;273:53-62.
62. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA, Jr., Luster AD, Luscinskas FW, Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999;398:718-723.
63. Issekutz A, Ripley M, Bhimji S. Quantitation of polymorphonuclear leukocyte migration under agarose by enzyme assay. J Immunol Methods 1983;59:19-28.
64. Stickle DF, Lauffenburger DA, Zigmond SH. Measurement of chemoattractant concentration profiles and diffusion coefficient in agarose. J Immunol Methods 1984;70:65-74.
65. Orr W, Ward PA. Quantitation of leukotaxis in agarose by three different methods. J Immunol Methods 1978;20:95-107.
66. Laevsky G, Knecht DA. Under-agarose folate chemotaxis of Dictyostelium discoideum amoebae in permissive and mechanically inhibited conditions. Biotechniques 2001;31:1140-1142, 1144, 1146-1149.
67. Hadjout N, Laevsky G, Knecht DA, Lynes MA. Automated real-time measurement of chemotactic cell motility. Biotechniques 2001;31:1130-1138.
68. Zigmond SH. Ability of polymorphonuclear leukocytes to orient in gradients of chemotactic factors. J Cell Biol 1977;75:606-616.
69. Zicha D, Dunn GA, Brown AF. A new direct-viewing chemotaxis chamber. J Cell Sci 1991;99:769-775.
70. Allen WE, Zicha D, Ridley AJ, Jones GE. A role for Cdc42 in macrophage chemotaxis. J Cell Biol 1998;141:1147-1157.
71. Webb SE, Pollard JW, Jones GE. Direct observation and quantification of macrophage chemoattraction to the growth factor CSF-1. J Cell Sci 1996;109(Pt 4):793-803.
72. Zicha D, Dunn G, Jones G. Analyzing chemotaxis using the Dunn direct-viewing chamber. Methods Mol Biol 1997;75:449-457.
73. Pelletier AJ, van der Laan LJ, Hildbrand P, Siani MA, Thompson DA, Dawson PE, Torbett BE, Salomon DR. Presentation of chemokine SDF-1 alpha by fibronectin mediates directed migration of T cells. Blood 2000;96:2682-2690.
74. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980;26:171-176.
75. Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 1977;19:621-626.
76. Mantovani A. The chemokine system: Redundancy for robust outputs. Immunol Today 1999;20:254-257.
77. Rodriguez-Frade JM, Mellado M, Martinez AC. Chemokine receptor dimerization: Two are better than one. Trends Immunol 2001;22:612-617.
78. Gurrath M. Peptide-binding G protein-coupled receptors: New opportunities for drug design. Curr Med Chem 2001;8:1605-1648.
79. Klabunde T, Hessler G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem 2002;3:928-944.
80. Saunders J, Tarby CM. Opportunities for novel therapeutic agents acting at chemokine receptors. Drug Discov Today 1999;4:80-92.
81. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994;91:3652-3656.
82. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990;347:669-671.
83. Taub DD, Sayers TJ, Carter CR, Ortaldo JR. Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol 1995;155:3877-3888.
84. Dahinden CA, Geiser T, Brunner T, ron Tscharner V, Caput D, Ferrara P, Minty A, Baggiolini M. Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine. J Exp Med 1994;179:751-756.
85. Walz A, Peveri P, Aschauer H, Baggiolini M. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem Biophys Res Commun 1987;149:755-761.
86. Bacon KB, Westwick J, Camp RD. Potent and specific inhibition of IL-8-, IL-1 alpha- and IL-1 beta-induced in vitro human lymphocyte migration by calcium channel antagonists. Biochem Biophys Res Commun 1989;165:349-354.
87. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-833.
88. Hannigan M, Zhan L, Li Z, Ai Y, Wu D, Huang CK. Neutrophils lacking phosphoinositide 3-kinase gamma show loss of directionality during N-formyl-Met-Leu-Phe-induced chemotaxis. Proc Natl Acad Sci USA 2002;99:3603-3608.
89. Goetzl EJ. Modulation of human neutrophil polymorphonuclear leucocyte migration by human plasma alpha-globulin inhibitors and synthetic esterase inhibitors. Immunology 1975;29:163-174.
90. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987;84:5788-5792.
91. Brandes ME, Mai UE, Ohura K, Wahl SM. Type 1 transforming growth factor-beta receptors on neutrophils mediate chemotaxis to transforming growth factor-beta. J Immunol 1991;147:1600-1606.
92. Kimura T, Watanabe T, Sato K, Kon J, Tomura H, Tamama K, Kuwabara A, Kanda T, Kobayashi I, Ohta H, Ui M, Okajima F. Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. Biochem J 2000;348(Pt 1):71-76.
93. Graeler M, Goetzl EJ. Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J 2002;16:1874-1878.
94. Idzko M, Panther E, Corinti S, Morelli A, Ferrari D, Herouy Y, Dichmann S, Mockenhaupt M, Gebicke-Haerter P, Di Virgilio F, Girolomoni G, Norgauer J. Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J 2002;16:625-627.
95. Kveberg L, Bryceson Y, Inngjerdingen M, Rolstad B, Maghazachi AA. Sphingosine 1 phosphate induces the chemotaxis of human natural killer cells. Role for heterotrimeric G proteins and phosphoinositide 3 kinases. Eur J Immunol 2002;32:1856-1864.
96. Zheng Y, Kong Y, Goetzl EJ. Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J Immunol 2001;166:2317-2322.
97. English D, Kovala AT, Welch Z, Harvey KA, Siddiqui RA, Brindley DN, Garcia JG. Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis. J Hematother Stem Cell Res 1999;8:627-634.
98. Sakai T, Peyruchaud O, Fassler R, Mosher DF. Restoration of beta1A integrins is required for lysophosphatidic acid-induced migration of beta1-null mouse fibroblastic cells. J Biol Chem 1998; 273:19378-19382.
99. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, Nagata K. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193:255-261.
100. Palmblad J, Malmsten CL, Uden AM, Radmark O, Engstedt L, Samuelsson B. Leukotriene B4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. Blood 1981;58:658-661.
101. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980;286:264-265.
102. Potter KA, Leid RW, Kolattukudy PE, Espelie KE. Stimulation of equine eosinophil migration by hydroxyacid metabolites of arachidonic acid. Am J Pathol 1985;121:361-368.
103. Morita E, Schroder JM, Christophers E. Differential sensitivities of purified human eosinophils and neutrophils to defined chemotaxins. Scand J Immunol 1989;29:709-716.
104. Goetzl EJ, Woods JM, Gorman RR. Stimulation of human eosinophil and neutrophil polymorphonuclear leukocyte chemotaxis and random migration by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid. J Clin Invest 1977;59:179-183.
105. Goetzl EJ. A role for endogenous mono-hydroxy-eicosatetraenoic acids (HETEs) in the regulation of human neutrophil migration. Immunology 1980;40:709-719.
106. Nakao J, Ooyama T, Chang WC, Murota S, Orimo H. Platelets stimulate aortic smooth muscle cell migration in vitro. Involvement of 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid. Atherosclerosis 1982;43:143-150.
107. Harvath L, Falk W, Leonard EJ. Rapid quantitation of neutrophil chemotaxis: Use of a polyvinylpyrrolidone-free polycarbonate membrane in a multiwell assembly. J Immunol Methods 1980;37:39-45.
108. De Clerck LS, Bridts CH, Mertens AM, Moens MM, Stevens WJ. Use of fluorescent dyes in the determination of adherence of human leucocytes to endothelial cells and the effect of fluorochromes on cellular function. J Immunol Methods 1994;172:115-124.
109. Denholm EM, Stankus GP. Differential effects of two fluorescent probes on macrophage migration as assessed by manual and automated methods. Cytometry 1995;19:366-369.
110. Sunder-Plassmann G, Hofbauer R, Sengoelge G, Horl WH. Quantification of leukocyte migration: Improvement of a method. Immunol Invest 1996;25:49-63.
111. Shi Y, Kornovski BS, Savani R, Turley EA. A rapid, multiwell colorimetric assay for chemotaxis. J Immunol Methods 1993;164:149-154.
112. Wilkinson PC, Haston WS, Shields JM. Some determinants of the locomotory behavior of phagocytes and lymphocytes in vitro. Clin Exp Immunol 1982;50:461-473.
113. Zicha D, Dunn GA. Are growth factors chemotactic agents? Exp Cell Res 1995;221:526-529.
114. Horuk R, Ng HP. Chemokine receptor antagonists. Med Res Rev 2000;20:155-168.
115. Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 2002;42:469-499.
116. Beech JS, Reckless J, Mosedale DE, Grainger DJ, Williams SC, Menon DK. Neuroprotection in ischemia-reperfusion injury: An antiinflammatory approach using a novel broad-spectrum chemokine inhibitor. J Cereb Blood Flow Metab 2001;21:683-689.
117. Fox DJ, Reckless J, Warren SG, Grainger DJ. Design, synthesis, and preliminary pharmacological evaluation of N-acyl-3-aminoglutarimides as broad-spectrum chemokine inhibitors in vitro and anti-inflammatory agents in vivo. J Med Chem 2002;45:360-370.